8 April 2019 |
DMTC is a not for profit collaborative venture that brings together defence industry, universities and government research agencies to develop technologies that will enhance Australia’s defence and national security capability.
The national Medical Countermeasures (MCM) activity led by DMTC is focused on vaccines, therapeutics and diagnostics for the protection of military and civilian personnel against Chemical Biological and Radiological (CBR) threats, emerging infectious diseases and pandemics.
This call for collaborative project proposals focuses on three priority themes:
- Point of Care Diagnostics
- Antimicrobial Resistance and
- Security Sensitive Biological Agents.
In addition, proposals are welcomed for therapeutics against chemical threats, regional tropical diseases such as Malaria and Dengue; and Alphaviruses.
Proposed projects are expected to have at least one industry partner and one research/academic partner. The DMTC MCM program is about translation of technology and therefore all proposed projects must be at or above the non-clinical/preclinical phase of development for vaccines and therapeutics; and prototype development for diagnostics.
QuadCharts are required to be submitted by email to mcm.eoi@dmtc.com.au by no later than 1600hrs AEST on 6 May 2019. Project proposals that are down-selected will proceed to a more detailed White Paper Proposal stage. Proposers will be notified by 20 May 2019.
Further information and requests for briefings
Questions about this EOI process or requests for briefings should be directed to Dr Felicia Pradera at DMTC via mcm.eoi@dmtc.com.au. Responses to generic questions will be made available on the DMTC MCM website. Face-to-face briefings may also be arranged if there is sufficient interest.
The following guidance is available to assist with applications:
